A 42-year-old Indian man presents with severe hypercholesterolaemia (LDL 520 mg/dL), premature coronary artery disease at age 38, and Achilles tendon xanthomas. Genetic testing reveals a heterozygous PCSK9 gain-of-function mutation. Which feature best distinguishes this PCSK9-FH phenotype from LDLR-FH?

Explanation

## PCSK9-FH vs. LDLR-FH: Mechanistic Distinction ### Pathophysiological Difference **Key Point:** PCSK9 gain-of-function mutations cause FH by increasing degradation of LDL receptors, whereas LDLR mutations cause FH by reducing LDL receptor synthesis or function. This mechanistic difference has profound therapeutic implications. ### Molecular Mechanism Comparison | Aspect | LDLR-FH | PCSK9-FH | | --- | --- | --- | | **Genetic defect** | Loss-of-function: LDLR gene mutation | Gain-of-function: PCSK9 gene mutation | | **Mechanism** | ↓ LDL receptor synthesis or trafficking | ↑ PCSK9 → ↑ LDLR degradation (ubiquitin-mediated) | | **LDL receptor status** | Reduced number; may be dysfunctional | Normal or near-normal number; but rapidly degraded | | **PCSK9 inhibitor response** | Modest benefit (receptors already low) | Excellent benefit (prevents LDLR degradation, rescues receptors) | | **Statin response** | Moderate (limited receptor upregulation) | Moderate (statin upregulates LDLR, but PCSK9 still degrades them) | | **Statin + PCSK9i** | Additive; good response | Synergistic; excellent response | ### Mechanism Diagram ```mermaid flowchart TD A[Hepatocyte]:::outcome B[LDLR gene]:::outcome C[LDLR protein synthesis]:::action D[LDLR on cell surface]:::outcome E[LDL uptake]:::action F[PCSK9 protein]:::outcome G[LDLR ubiquitination]:::action H[LDLR degradation]:::urgent B -->|Normal| C C -->|Normal| D D -->|Normal| E F -->|Gain-of-function| G G --> H D -->|PCSK9 binds| H I[PCSK9 inhibitor]:::action I -->|Blocks PCSK9| F I -.->|Rescues LDLR| D J[LDLR mutation]:::urgent J -->|Loss-of-function| C J -->|↓ Receptors| E ``` ### High-Yield Clinical Insight **High-Yield:** PCSK9 inhibitors (evolocumab, alirocumab) are **dramatically more effective** in PCSK9-FH than in LDLR-FH because: - In PCSK9-FH: Blocking PCSK9 prevents LDLR degradation → receptors accumulate on cell surface → LDL uptake ↑↑ - In LDLR-FH: LDLR numbers are already low; PCSK9i cannot create receptors that don't exist → benefit is modest In PCSK9-FH, PCSK9 inhibitors can reduce LDL by 50–70%; in LDLR-FH, the reduction is typically 20–30%. ### Clinical Pearl **Clinical Pearl:** A patient with FH who has an **excellent response** to PCSK9 inhibitor monotherapy (LDL drops >60%) likely has PCSK9-FH. A patient with FH who has a **poor response** to PCSK9i alone likely has LDLR-FH and may benefit from ezetimibe, bempedoic acid, or inclisiran (PCSK9 siRNA) instead. ### Why This Matters Genetic diagnosis (LDLR vs. PCSK9) guides therapy: - PCSK9-FH → PCSK9i is first-line add-on - LDLR-FH → ezetimibe, inclisiran, or apheresis may be preferred **Warning:** Do not assume all FH patients respond equally to PCSK9 inhibitors. Genotype predicts phenotypic response.